NSI-189

Quick Verdict

A genuinely novel mechanism in a field that desperately needs one: hippocampal neurogenesis unrelated to traditional antidepressant pathways. Then the Phase 2 results came in. The objective depression scores improved but did not reach statistical significance on the primary endpoint. Patient self-reported measures were positive. That split is either a measurement problem or a drug problem, and nobody knows which. Sentiment is 65/100 across 5 tracked studies.

Evidence Quality

• Human trials: Weak (Phase 2 for depression with mixed results; no Phase 3 initiated)
• Animal evidence: Moderate (hippocampal volume increase measurable on MRI in animal models; NSI-189 significantly improved motor and neurological function in stroke rats)
• Community reports: Moderate (research chemical community reports are mixed; some dramatic positive responses, many non-responders)
• Key uncertainty: Whether the Phase 2 failure on the clinician-rated primary endpoint but success on patient-rated secondary endpoints reflects a real effect that was poorly measured, or wishful thinking in the subjective scores.

What the Research Shows

A Phase 2 double-blind, placebo-controlled study found NSI-189 did not significantly reduce depression versus placebo, though the 40mg dose improved certain secondary cognitive measures. A Phase 1B study showed promising reductions in depressive and cognitive symptoms. Research demonstrates NSI-189 enhanced long-term potentiation and reversed impairments in a mouse model of Angelman Syndrome. In stroke rats, oral NSI-189 significantly improved motor and neurological function and promoted brain cell growth. The mechanism (hippocampal neurogenesis) is distinct from anything else available. Neuralstem has not publicly announced plans for Phase 3, which is not an encouraging signal for the compound’s commercial future.

Who Should Be Cautious

This is an unregulated research chemical. Anyone with bipolar disorder should be cautious with any neurogenic compound due to theoretical mania risk. Those on other antidepressants should consider interaction potential that has not been characterized.

What This Page Cannot Tell You

Whether NSI-189 will ever reach Phase 3 trials. The compound may work, but if no company funds the trials to prove it, that question may never be answered through the regulatory process.